KALA$0.6135
Chart
Performance
Key Stats
AI KALA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldKALA BIO, Inc. operates in a high-growth sector with promising therapeutic development. However, current financial performance indicates significant losses and a lack of revenue, making it a speculative investment with high risk and uncertain short-term returns. Long-term potential exists if clinical trials are successful and commercialization is achieved.
Thematic
KALA BIO, Inc. is positioned in the biopharmaceutical sector, focusing on rare and severe eye diseases. This area benefits from aging demographics, increased healthcare spending, and advancements in genetic and regenerative medicine. The company's focus on unmet medical needs is a positive thematic driver.
Fundamental
KALA BIO, Inc. exhibits a weak fundamental profile characterized by significant operating losses, no revenue generation from approved products, and substantial cash burn. While the company maintains a healthy cash position, its path to profitability is unproven.
Technical
KALA BIO, Inc. has experienced strong short-term performance, with significant gains over the past month and 5-day period. However, longer-term performance is mixed, and technical indicators suggest the stock is approaching overbought levels, implying potential for a short-term pullback.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 85 |
| Rare Disease Market | 80 |
| Aging Population | 70 |
| Regulatory Landscape (FDA Approval) | 60 |
| Competitive Landscape | 70 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 10 |
| Balance Sheet Health | 40 |
| Cash Flow | 30 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 55 |
| Volume Confirmation | 65 |
| Support & Resistance | 50 |
| Recent Performance | 80 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Short-Term Performance
The stock has shown significant positive returns over shorter periods, with a 5-day performance of 47.09% and a 1-month performance of 75.11%.
High Liquidity
The company has substantial cash equivalents ($51,181,000 as of 2024Q4) relative to its short-term debt, indicating a good ability to meet immediate obligations.
Bearish Points (8)
Negative Earnings
The company has consistently reported negative EPS (e.g., -7.36 for EPS TTM) and negative net income in recent years, leading to non-meaningful P/E ratios.
No Revenue Growth
The company reported zero revenue for 2024Q4, 2023Q4, and 2022Q4, with only minimal revenue in 2021 and 2022, indicating a lack of commercial product sales.
Calendar
August 2025
4
Next Earnings Date
H: $-2.04
A: $-2.04
L: $-2.04
Profile
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Seasonals
Price Target
13.00 USD
The 39 analysts offering 1 year price forecasts for KALA have a max estimate of 15.00 and a min estimate of 12.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Direct competitor to KALA BIO, Inc. in the wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) markets with its blockbuster drug, Eylea.
Weight: 98
Significant player in ophthalmology, direct competitor in wet AMD and DME with drugs like Lucentis and Beovu.
Weight: 97
Through its subsidiary Genentech, developed and markets Lucentis, a key treatment for wet AMD and DME, directly competing with KALA's focus.
Weight: 95
Biopharmaceutical company focused on developing novel therapeutics for retinal diseases, including wet AMD and DME, making it a direct pipeline competitor.